Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) — Biostax Corp (OTC Pink: BIOX) (“Biostax” or “the Company”), a biopharmaceutical company focused on developing innovative immune restoration therapies, today announced its Board of Directors has approved and the Company intends to proceed with the voluntary delisting of its common stock from the OTC Pink marketplace. This strategic decision follows strong shareholder support, with 76.4% voting in favor of the delisting through a Joint Written Consent.

The Company plans to file a Form 25 with the Securities and Exchange Commission (SEC) on March 15, 2025, initiating the delisting process. The delisting is expected to become effective ten days after the filing. Concurrent with the Form 25, Biostax will file a Form 15 to deregister its common stock under the Securities Exchange Act of 1934.

“After careful consideration of our strategic options, we have determined that delisting will better position Biostax to execute on our long-term growth strategy,” said Noreen Griffin, Chief Executive Officer of Biostax. “We believe our current public market valuation does not adequately reflect our achievements and future potential. Operating as a private company will provide us greater flexibility to focus on advancing our promising drug candidates while reducing the administrative burden and costs associated with maintaining a public listing.”

The decision aligns with Biostax’s commitment to advancing its robust pipeline, including:

  • JKB-122, which has received FDA authorization to proceed with clinical trials for:
    • Autoimmune Hepatitis in newly diagnosed patients
    • Phase 2 trials for NASH and NAFLD
  • Planned IND filing for JKB-122 as an adjunct therapy in HIV treatment, targeting immune activation and chronic inflammation reduction in non-responders or patients failing current therapies

Following the effectiveness of the Form 25 filing, the Company’s common stock will no longer be traded on the OTC Pink marketplace. Biostax remains committed to maintaining transparent communication with its shareholders and will provide updates on significant developments as appropriate.

About Biostax Corp

Biostax is dedicated to developing affordable, sustainable healthcare solutions focusing on immune restoration and inflammation reduction. The Company’s approach targets key factors in the pathogenesis of numerous diseases, with demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models. Our mission is to develop therapies that achieve disease remission by restoring immune balance in patients with autoimmune, inflammatory, and infectious diseases, without suppressing their immune system. For more information, visit www.biostaxcorp.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding Biostax’s business strategies, clinical development programs, and expectations regarding future operations. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from those projected, including regulatory reviews, clinical trial outcomes, and market conditions. Biostax does not undertake any obligation to update these forward-looking statements, except as required by law. Please refer to our SEC filings for a more detailed discussion of potential risks and uncertainties.

Contact:

Noreen M. Griffin

Chief Executive Officer

Biostax Corp Email: ir@biostax.net

Staff

Recent Posts

CORRECTING and REPLACING Vouched Developing Integration in Epic Toolbox Under Construction for Remote Identity Verification

Integration Empowers Hospitals to Streamline Patient Onboarding, Enhance Compliance, and Improve Care Delivery with Seamless…

8 hours ago

BLUE & CO., LLC PROVIDES NOTICE OF DATA EVENT

CARMEL, Ind., July 3, 2025 /PRNewswire/ -- Blue & Co., LLC ("Blue") is a financial…

11 hours ago

Dr. Aubrey de Grey Brings Cutting-Edge Science to RAADfest 2025: LEV Foundation Partners with Coalition for Radical Life Extension

Renowned biogerontologist Dr. Aubrey de Grey to curate specialized scientific programming at world's leading longevity…

11 hours ago

NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth

Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic…

12 hours ago

ScienceSoft Raises the Bar for AI Voice Scheduling in Healthcare

MCKINNEY, Texas--(BUSINESS WIRE)--#AI--Human-Like, Real-Time AI Scheduler launched by ScienceSoft ScienceSoft has introduced a HIPAA-compliant AI…

14 hours ago

New Podcast “Spreading the Good BUZZ” Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives

Through Hope and Community in Recovery, Sober.Buzz along with @SoberBuzzToken on Instagram are Impacting and…

17 hours ago